Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics.

Shumei KatoJacob J AdashekJustin ShayaRyosuke OkamuraRebecca E JimenezSuzanna LeeJason K SicklickRazelle Kurzrock

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

These observations suggest that cotargeting cyclin and MEK signaling can be successful when tumors bear genomic coalterations that activate both of these pathways. Further prospective studies using this matching precision strategy to overcome resistance are warranted.See related commentary by Groisberg and Subbiah, p. 2672.

Keyphrases

cell cycle
pi k akt
cell cycle arrest
copy number
signaling pathway
cell proliferation
genome wide
small molecule
cancer therapy
case control
gene expression
cell death
genome wide identification
drug delivery
genome wide analysis